ARMATA PHARMACEUTICALS, INC. Retained Earnings
ARMATA PHARMACEUTICALS, INC. (ARMP) had Retained Earnings of -$542.74 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-12
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$542.74M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$616.88M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$501.53M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$377.24M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$542.74M 10-Q · filed 2026-08-12 | |
| 2026-03-31 | -$616.88M 10-Q · filed 2026-05-13 | |
| 2025-12-31 | -$501.53M 10-Q · filed 2026-08-12 | |
| 2025-09-30 | -$377.24M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | -$350.56M 10-Q · filed 2025-08-12 | |
| 2025-03-31 | -$334.27M 10-Q · filed 2025-05-14 | |
| 2024-12-31 | -$327.74M 10-K · filed 2026-03-25 | |
| 2024-09-30 | -$330.33M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | -$324.85M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | -$333.84M 10-Q · filed 2024-05-07 | |
| 2023-12-31 | -$308.82M 10-K · filed 2025-03-21 | |
| 2023-09-30 | -$288.97M 10-Q · filed 2023-11-14 | |
| 2023-06-30 | -$257.81M 10-Q · filed 2023-08-14 | |
| 2023-03-31 | -$254.26M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | -$239.77M 10-K · filed 2024-03-21 | |
| 2022-09-30 | -$229.46M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | -$220.85M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | -$211.63M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | -$202.86M 10-K · filed 2023-03-16 | |
| 2021-09-30 | -$196.81M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | -$191.39M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | -$185.20M 10-Q · filed 2021-05-13 | |
| 2020-12-31 | -$179.70M 10-K · filed 2022-03-17 | |
| 2020-09-30 | -$173.08M 10-Q · filed 2020-11-12 | |
| 2020-06-30 | -$167.31M 10-Q · filed 2020-08-13 | |
| 2020-03-31 | -$162.60M 10-Q · filed 2020-05-14 | |
| 2019-12-31 | -$157.52M 10-K · filed 2021-03-18 | |
| 2019-09-30 | -$152.94M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | -$145.98M 10-Q · filed 2019-08-14 | |
| 2019-03-31 | -$409.93M 10-Q · filed 2019-05-06 | |
| 2018-12-31 | -$138.04M 10-K · filed 2020-03-19 | -$406.32M 10-K · filed 2019-03-25 |
| 2018-09-30 | -$402.00M 10-Q · filed 2018-11-08 | |
| 2018-06-30 | -$400.39M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | -$397.34M 10-Q · filed 2018-05-15 | |
| 2017-12-31 | -$394.21M 10-K · filed 2019-03-25 | |
| 2017-09-30 | -$391.85M 10-Q · filed 2017-11-14 | |
| 2017-06-30 | -$391.07M 10-Q · filed 2017-08-14 | |
| 2017-03-31 | -$384.61M 10-Q · filed 2017-05-15 | |
| 2016-12-31 | -$381.36M 10-K · filed 2018-03-14 | |
| 2016-09-30 | -$371.86M 10-Q · filed 2016-11-10 | |
| 2016-06-30 | -$369.49M 10-Q · filed 2016-08-15 | |
| 2016-03-31 | -$365.63M 10-Q · filed 2016-05-12 | |
| 2015-12-31 | -$362.52M 10-K · filed 2017-03-27 | |
| 2015-09-30 | -$360.29M 10-Q · filed 2015-11-16 | |
| 2015-06-30 | -$365.73M 10-Q · filed 2015-08-13 | |
| 2015-03-31 | -$376.50M 10-Q · filed 2015-05-15 | |
| 2014-12-31 | -$362.01M 10-K · filed 2016-03-30 | |
| 2014-09-30 | -$361.34M 10-Q/A · filed 2015-04-15 | -$355.31M 10-Q · filed 2014-11-14 |
| 2014-06-30 | -$382.55M 10-Q/A · filed 2015-04-15 | -$374.70M 10-Q · filed 2014-09-12 |
| 2014-03-31 | -$396.42M 10-Q/A · filed 2015-04-15 | -$394.83M 10-Q · filed 2014-05-20 |
| 2013-12-31 | -$385.12M 10-Q/A · filed 2015-04-15 | -$384.69M 10-Q · filed 2014-05-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |